| Lignocaine and indocyanine green kinetics in patients following myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 7448106 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
1. Blood clearances of lignocaine and indocyanine green together with indocyanine green half-lives were measured in 17 post-myocardial infarct patients (one patient was studied twice) between 8 h and 36 h after starting intravenous lignocaine infusions for the treatment of cardiac arrhythmias. 2. Mean +/- s.d. values of lignocaine clearance (ml min-1 kg-1) were higher in patients without heart failure (11.8 +/- 2.6, n = 9) than in those with heart failure (7.2 +/- 1.9, n = 9) (P < 0002). 3. Clearances of lignocaine and indocyanine green were not correlated but lignocaine clearance was directly related to the reciprocal of indocyanine green half-life (rs = 0.67, P < 0.01). 4. In eight patients who received both lignocaine and indocyanine green and in a further five patients received only lignocaine and whose lignocaine infusions lasted 24h or more, a 25% rise in lignocaine concentrations was observed between 8-12h and 24-28h. 5. The mean +/- s.d. post-infusion terminal half-life of lignocaine in four patients whose lignocaine infusions lasted 30h or longer was 7.2 +/- 2.1 h. 6. Heart failure was associated with greater changes in lignocaine kinetics than in indocyanine green kinetics. 72% of the variance between observed and predicted lignocaine clearances could be accounted for by multiple linear regression analysis incorporating indocyanine green half-life and the presence or absence of heart failure. Indocyanine green half-life contributed only 17% of the variance indicating that by itself it is of limited value in predicting lignocaine requirements. 7. Lignocaine kinetics during and after prolonged intravenous infusion were not predicted by data obtained after intravenous bolus injection. 8. A lowering of lignocaine dosage may be clinically desirable in the presence of heart failure and if an infusion lasts longer than 24 h. |
| | |
Authors:
|
N D Bax; G T Tucker; H F Woods |
Related Documents
:
|
20937286 - Protein kinase cα as a heart failure therapeutic target. 16003646 - Diagnostic criteria for diastolic heart failure. 10735676 - Composite cardiac binding in experimental heart failure. 3311456 - Elevated pulmonary vascular resistance and cardiac transplantation. 20197586 - St-segment elevation myocardial infarction in severe coronary artery stenosis: a case s... 11149636 - Coronary reoperations: indications, techniques and operative results. retrospective stu... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 10 ISSN: 0306-5251 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 1980 Oct |
Date Detail:
|
Created Date: 1981-03-24 Completed Date: 1981-03-24 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 353-61 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Female Half-Life Heart Failure / metabolism* Humans Indocyanine Green / metabolism* Kinetics Lidocaine / metabolism* Male Metabolic Clearance Rate Middle Aged Myocardial Infarction / metabolism* Regression Analysis |
| Chemical | |
Reg. No./Substance:
|
137-58-6/Lidocaine; 3599-32-4/Indocyanine Green |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Obstetric anaesthesia and Ehlers-Danlos syndrome.
Next Document: Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery.